home / open_comments

documents

Federal regulatory documents currently open for public comment. ⚠ Derive comment deadlines from comment_end_datetime converted to America/New_York, never from comment_end_date, which is mid-correction and may be one day late (DataDawn queue #498).

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

perpetual_docket
1 = a standing/perpetual docket carrying a sentinel comment-end date (2050 or later; in practice 2099/2100 — agency guidance and exemption dockets that never close). 0 = an ordinary docket with a real deadline. NULL = no end date reported. The site's Open-for-Comment surface EXCLUDES perpetual_docket = 1 by default, so the site count and the bulk dump answer the same question differently: the dump is complete and includes them.
comment_end_date
The comment deadline as an Eastern (America/New_York) calendar date — CORRECTED in the 2026-09-06 daily snapshot (DataDawn queue #498): a snapshot whose _metadata row comment_end_date_grain reads 'eastern' carries the Eastern date; the pre-correction snapshots (through 2026-09-05) held the UTC-rolled day, one day LATE on every end-of-day close. Federal comment periods close at 11:59:59 PM Eastern and the source publishes that instant in UTC ('2026-08-26T03:59:59Z' = the 2026-08-25 deadline). Prefer comment_end_datetime for any arithmetic and convert it to America/New_York yourself; never 'subtract a day' from this column.
comment_end_datetime
AUTHORITATIVE. The full UTC instant of the comment deadline ('2026-08-26 03:59:59' == 11:59:59 PM Eastern on 2026-08-25). Convert to America/New_York for the official date; prefer this column over comment_end_date for anything computed.

69 rows where agency_id = "FDA" and document_type = "Other" sorted by comment_end_datetime descending

✎ View and edit SQL

This data as json, CSV (advanced)

document_type 1

  • Other · 69 ✖

agency_id 1

  • FDA · 69 ✖
id agency_id docket_id title document_type subtype posted_date posted_year posted_month comment_start_date comment_end_date comment_end_datetime ▲ perpetual_docket last_modified fr_doc_num open_for_comment withdrawn object_id
FDA-2026-N-7864-0001 FDA FDA-2026-N-7864 Data Request (DR001): Use of the pH Cycling Test Model as a Testing Procedure for Fluoride Dentifrice Drug Products in Over-the-Counter (OTC) Monograph M021: Anticaries Drug Products for Over-the-Counter Human Use Other Request 2026-07-28 2026 7 2026-07-28 2027-01-25 2027-01-26 04:59:59 0 2026-07-28 16:50:16   1 0 09000064b93c7444
FDA-2026-D-8693-0002 FDA FDA-2026-D-8693 Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosage; Guidance for Industry; Draft Guidance for Industry Other Guidance 2026-09-02 2026 9 2026-09-02 2026-12-01 2026-12-02 04:59:59 0 2026-09-03 00:56:30   1 0 09000064b94bc729
FDA-2012-N-1021-0107 FDA FDA-2012-N-1021 Instructions for Submitting Comments on the CDRH Fiscal Year 2027 Proposed Guidance Development Other Additional Information 2026-10-01 2026 10 2026-10-01 2026-11-30 2026-12-01 04:59:59 0 2026-10-10 09:00:58   1 0 09000064b95fb842
FDA-2018-D-4533-2364 FDA FDA-2018-D-4533 Compounding Animal Drugs from Bulk Drug Substances: Compounding under CGMP in Federally-Registered Facilities; Draft Guidance Other Guidance 2026-08-28 2026 8 2026-08-28 2026-11-27 2026-11-28 04:59:59 0 2026-10-06 09:00:30   1 0 09000064b94a6e26
FDA-2026-P-5995-0001 FDA FDA-2026-P-5995 Suitability Petition from Hyman, Phelps, & McNamara P.C. Other Petition(s) 2026-05-28 2026 5 2026-05-28 2026-11-24 2026-11-25 04:59:59 0 2026-09-29 15:44:43   1 0 09000064b92f59e1
FDA-2026-N-9505-0002 FDA FDA-2026-N-9505 Robotically-Assisted Surgical Devices - Premarket Submissions; Draft Guidance for Industry and Food and Drug Administration Staff; Draft Guidance Other Guidance 2026-09-25 2026 9 2026-09-25 2026-11-24 2026-11-25 04:59:59 0 2026-10-13 09:01:01   1 0 09000064b95c6e19
FDA-2026-N-8563-0001 FDA FDA-2026-N-8563 Regulatory Science Innovations Catalyzing Medical Device Development_Co-sponsored Public Meeting Other Meeting 2026-08-06 2026 8 2026-08-06 2026-11-24 2026-11-25 04:59:59 0 2026-10-14 09:00:37   1 0 09000064b940e756
FDA-2025-D-6952-0002 FDA FDA-2025-D-6952 Requirements for Additional Traceability Records for Certain Foods: Enforcement Policy for Certain Retail Food Establishments and Restaurants: Guidance for Industry - Draft Guidance Other Guidance 2026-10-09 2026 10 2026-10-09 2026-11-23 2026-11-24 04:59:59 0 2026-10-14 09:01:00   1 0 09000064b96574d6
FDA-2026-D-8561-0002 FDA FDA-2026-D-8561 Potency Assessment of Active Immunotherapy Products; Draft Guidance for Industry Other Guidance 2026-08-20 2026 8 2026-08-20 2026-11-18 2026-11-19 04:59:59 0 2026-08-20 17:59:44   1 0 09000064b946ee4d
FDA-2026-D-9429-0002 FDA FDA-2026-D-9429 Electronic Submission Template for Premarket Approval Applications (PMAs); Draft Guidance for Industry and Food and Drug Administration Staff - Draft Guidance Other Guidance 2026-09-18 2026 9 2026-09-18 2026-11-17 2026-11-18 04:59:59 0 2026-09-18 18:06:45   1 0 09000064b95876d8
FDA-2025-N-2787-0008 FDA FDA-2025-N-2787 BsUFA III Future Needs for the Development of Interchangeable Products; Post-Workshop Strategy Document Other Request 2026-09-18 2026 9 2026-09-18 2026-11-17 2026-11-18 04:59:59 0 2026-09-25 09:00:32   1 0 09000064b9592e12
FDA-2026-D-7233-0002 FDA FDA-2026-D-7233 Target Animal Safety Evaluation for Veterinary Monoclonal Antibody Products VICH GL62; Guidance for Industry (GFI) #298 - Draft Guidance Other Guidance 2026-09-18 2026 9 2026-09-18 2026-11-17 2026-11-18 04:59:59 0 2026-09-25 09:00:32   1 0 09000064b958e85f
FDA-2026-N-7914-0001 FDA FDA-2026-N-7914 Public Meeting on Listeria monocytogenes Prevention Other Additional Information 2026-08-03 2026 8 2026-08-03 2026-11-02 2026-11-03 04:59:59 0 2026-08-19 09:01:12   1 0 09000064b93e5b66
FDA-2007-D-0369-2652 FDA FDA-2007-D-0369 PSG_020816 - Draft Guidance on Brinzolamide Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:08:40   1 0 09000064b9470607
FDA-2007-D-0369-2653 FDA FDA-2007-D-0369 PSG_020732 - Draft Guidance on Buprenorphine Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:08:45   1 0 09000064b94706ae
FDA-2007-D-0369-2654 FDA FDA-2007-D-0369 PSG_204370 - Draft Guidance on Cariprazine Hydrochloride Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:08:55   1 0 09000064b94706b0
FDA-2007-D-0369-2655 FDA FDA-2007-D-0369 PSG_050600 - Draft Guidance on Clindamycin Phosphate Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:09:04   1 0 09000064b94706b2
FDA-2007-D-0369-2656 FDA FDA-2007-D-0369 PSG_215425 - Draft Guidance on Epinephrine Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:09:08   1 0 09000064b94706b4
FDA-2007-D-0369-2657 FDA FDA-2007-D-0369 PSG_218475 - Draft Guidance on Epinephrine Bitartrate Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:09:13   1 0 09000064b94706b6
FDA-2007-D-0369-2658 FDA FDA-2007-D-0369 PSG_203565 - Draft Guidance on Ferric Carboxymaltose Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:09:18   1 0 09000064b94706b8
FDA-2007-D-0369-2659 FDA FDA-2007-D-0369 PSG_022180 - Draft Guidance on Ferumoxytol Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:09:23   1 0 09000064b94706ba
FDA-2007-D-0369-2660 FDA FDA-2007-D-0369 PSG_020243 - Draft Guidance on Fluvoxamine Maleate Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:09:28   1 0 09000064b94706bc
FDA-2007-D-0369-2661 FDA FDA-2007-D-0369 PSG_020496 - Draft Guidance on Glimepiride Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:09:33   1 0 09000064b94706be
FDA-2007-D-0369-2662 FDA FDA-2007-D-0369 PSG_213876 - Draft Guidance on Hydrocortisone Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:09:38   1 0 09000064b94706c0
FDA-2007-D-0369-2663 FDA FDA-2007-D-0369 PSG_206185 - Draft Guidance on Latanoprost Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:09:42   1 0 09000064b94706c2
FDA-2007-D-0369-2664 FDA FDA-2007-D-0369 PSG_209939 - Draft Guidance on Letermovir Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:10:09   1 0 09000064b94706c4
FDA-2007-D-0369-2665 FDA FDA-2007-D-0369 PSG_021343 - Draft Guidance on Leuprolide Acetate Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:10:14   1 0 09000064b94706c6
FDA-2007-D-0369-2666 FDA FDA-2007-D-0369 PSG_021379 - Draft Guidance on Leuprolide Acetate Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:10:19   1 0 09000064b94706c8
FDA-2007-D-0369-2667 FDA FDA-2007-D-0369 PSG_021731 - Draft Guidance on Leuprolide Acetate Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:10:24   1 0 09000064b94706ca
FDA-2007-D-0369-2668 FDA FDA-2007-D-0369 PSG_021924 - Draft Guidance on Levothyroxine Sodium Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:10:29   1 0 09000064b94706cc
FDA-2007-D-0369-2669 FDA FDA-2007-D-0369 PSG_215029 - Draft Guidance on Lidocaine Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:10:35   1 0 09000064b94706ce
FDA-2007-D-0369-2670 FDA FDA-2007-D-0369 PSG_021977 - Draft Guidance on Lisdexamfetamine Dimesylate Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:10:41   1 0 09000064b94706d0
FDA-2007-D-0369-2671 FDA FDA-2007-D-0369 PSG_219847 - Draft Guidance on Lisdexamfetamine Dimesylate Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:10:46   1 0 09000064b94706d2
FDA-2007-D-0369-2672 FDA FDA-2007-D-0369 PSG_219485 - Draft Guidance on Maralixibat Chloride Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:10:51   1 0 09000064b94706d4
FDA-2007-D-0369-2673 FDA FDA-2007-D-0369 PSG_214662 - Draft Guidance on Maralixibat Chloride Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:11:06   1 0 09000064b94706d6
FDA-2007-D-0369-2674 FDA FDA-2007-D-0369 PSG_217593 - Draft Guidance on Meloxicam Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:11:11   1 0 09000064b94706d8
FDA-2007-D-0369-2675 FDA FDA-2007-D-0369 PSG_218395 - Draft Guidance on Meloxicam Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:11:15   1 0 09000064b94706da
FDA-2007-D-0369-2676 FDA FDA-2007-D-0369 PSG_215211 - Draft Guidance on Miglustat Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:11:20   1 0 09000064b94706dc
FDA-2007-D-0369-2677 FDA FDA-2007-D-0369 PSG_020415 - Draft Guidance on Mirtazapine Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:11:25   1 0 09000064b94706de
FDA-2007-D-0369-2678 FDA FDA-2007-D-0369 PSG_215793 - Draft Guidance on Mitomycin Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:11:30   1 0 09000064b94706e0
FDA-2007-D-0369-2679 FDA FDA-2007-D-0369 PSG_203340 - Draft Guidance on Nimodipine Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:11:34   1 0 09000064b94706e2
FDA-2007-D-0369-2680 FDA FDA-2007-D-0369 PSG_021008 - Draft Guidance on Octreotide Acetate Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:11:40   1 0 09000064b9470826
FDA-2007-D-0369-2681 FDA FDA-2007-D-0369 PSG_208558 - Draft Guidance on Olaparib Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:11:45   1 0 09000064b9470828
FDA-2007-D-0369-2683 FDA FDA-2007-D-0369 PSG_020781 - Draft Guidance on Ondansetron Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:11:55   1 0 09000064b947082c
FDA-2007-D-0369-2684 FDA FDA-2007-D-0369 PSG_211150 - Draft Guidance on Pitolisant Hydrochloride Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:12:15   1 0 09000064b947082e
FDA-2007-D-0369-2685 FDA FDA-2007-D-0369 PSG_219685 - Draft Guidance on Rilzabrutinib Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:12:21   1 0 09000064b9470830
FDA-2007-D-0369-2686 FDA FDA-2007-D-0369 PSG_219301 - Draft Guidance on Sebetralstat Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:12:25   1 0 09000064b9470832
FDA-2007-D-0369-2687 FDA FDA-2007-D-0369 PSG_020573 - Draft Guidance on Sodium Phenylbutyrate Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:12:30   1 0 09000064b9470834
FDA-2007-D-0369-2688 FDA FDA-2007-D-0369 PSG_214860 - Draft Guidance on Sodium Phenylbutyrate Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:12:41   1 0 09000064b9470836
FDA-2007-D-0369-2689 FDA FDA-2007-D-0369 PSG_219839 - Draft Guidance on Sunvozertinib Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:12:46   1 0 09000064b9470838
FDA-2007-D-0369-2690 FDA FDA-2007-D-0369 PSG_219713 - Draft Guidance on Taletrectinib Adipate Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:12:51   1 0 09000064b947083a
FDA-2007-D-0369-2691 FDA FDA-2007-D-0369 PSG_211801 - Draft Guidance on Tenapanor Hydrochloride Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:12:55   1 0 09000064b947083d
FDA-2007-D-0369-2692 FDA FDA-2007-D-0369 PSG_219304 - Draft Guidance on Vimseltinib Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:13:07   1 0 09000064b947083f
FDA-2007-D-0369-2693 FDA FDA-2007-D-0369 PSG_021774 - Draft Guidance on Zolpidem Tartrate Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:13:14   1 0 09000064b9470841
FDA-2007-D-0369-2694 FDA FDA-2007-D-0369 PSG_021997 - Draft Guidance on Zolpidem Tartrate Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:13:19   1 0 09000064b9470843
FDA-2007-D-0369-2695 FDA FDA-2007-D-0369 PSG_022328 - Draft Guidance on Zolpidem Tartrate Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-08-24 20:13:25   1 0 09000064b9470845
FDA-2007-D-0369-2651 FDA FDA-2007-D-0369 PSG_204251 - Draft Guidance on Brimonidine Tartrate; Brinzolamide Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-09-29 20:51:16   1 0 09000064b9470605
FDA-2007-D-0369-2650 FDA FDA-2007-D-0369 PSG_217673 - Draft Guidance on Brensocatib Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-09-29 20:51:21   1 0 09000064b9470603
FDA-2007-D-0369-2649 FDA FDA-2007-D-0369 PSG_217729 - Draft Guidance on Bosutinib Monohydrate Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-09-29 20:51:28   1 0 09000064b9470601
FDA-2007-D-0369-2648 FDA FDA-2007-D-0369 PSG_217307 - Draft Guidance on Bimatoprost Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-09-29 20:51:33   1 0 09000064b94705ff
FDA-2007-D-0369-2647 FDA FDA-2007-D-0369 PSG_214902 - Draft Guidance on Benzoyl Peroxide; Tretinoin Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-09-29 20:51:38   1 0 09000064b94705fd
FDA-2007-D-0369-2645 FDA FDA-2007-D-0369 PSG_207924 - Draft Guidance on Baricitinib Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-09-29 20:51:48   1 0 09000064b94705f9
FDA-2007-D-0369-2644 FDA FDA-2007-D-0369 PSG_219696 - Draft Guidance on Avatrombopag Maleate Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-09-29 20:51:56   1 0 09000064b94705f7
FDA-2007-D-0369-2643 FDA FDA-2007-D-0369 PSG_210526 - Draft Guidance on Amphetamine;Amphetamine Aspartate/Dextroamphetamine Sulfate Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-09-29 20:52:01   1 0 09000064b94705f5
FDA-2007-D-0369-2642 FDA FDA-2007-D-0369 PSG_208147 - Draft Guidance on Amphetamine; Amphetamine Aspartate/Dextroamphetamine Sulfate Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-09-29 20:52:06   1 0 09000064b94705f3
FDA-2007-D-0369-2641 FDA FDA-2007-D-0369 PSG_204325 - Draft Guidance on Amphetamine Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-09-29 20:52:11   1 0 09000064b94705f1
FDA-2007-D-0369-2646 FDA FDA-2007-D-0369 PSG_214510 - Draft Guidance on Benzoyl Peroxide Other Guidance 2026-08-24 2026 8 2026-08-24 2026-10-23 2026-10-24 03:59:59 0 2026-09-29 20:52:49   1 0 09000064b94705fb
FDA-2017-D-5974-0013 FDA FDA-2017-D-5974 Determining Whether to Submit an ANDA or a 505(b)(2) Application; Guidance for Industry; Draft Guidance Other Guidance 2026-08-18 2026 8 2026-08-18 2026-10-19 2026-10-20 03:59:59 0 2026-09-27 09:00:23   1 0 09000064b9467762
FDA-2026-N-7874-0001 FDA FDA-2026-N-7874 Considerations for the Regulation of Generative AI-Enabled Medical Devices: Discussion Paper and Request for Feedback Other Request 2026-08-18 2026 8 2026-08-18 2026-10-19 2026-10-20 03:59:59 0 2026-10-15 09:00:27   1 0 09000064b9467189

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options:

CREATE TABLE documents (
            id TEXT PRIMARY KEY,
            agency_id TEXT,
            docket_id TEXT,
            title TEXT,
            document_type TEXT,
            subtype TEXT,
            posted_date TEXT,
            posted_year INTEGER,
            posted_month INTEGER,
            comment_start_date TEXT,
            comment_end_date TEXT,      -- EASTERN calendar date of the close (queue #498 writer
                                        -- fix, 2026-09-05; was the UTC-rolled day AFTER the ET
                                        -- deadline before that). Display-grade only.
            comment_end_datetime TEXT,  -- full UTC close ("YYYY-MM-DD HH:MM:SS", queue #498):
                                        -- the API expresses the 11:59:59 PM ET deadline as a UTC
                                        -- datetime. AUTHORITATIVE: the predicate, days_left and
                                        -- any timezone-aware render derive from THIS column.
            perpetual_docket INTEGER,   -- 1 = sentinel end date (queue #464); NULL = no end date
            last_modified TEXT,
            fr_doc_num TEXT,
            open_for_comment INTEGER,
            withdrawn INTEGER,
            object_id TEXT
        );
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_comment_end ON documents(comment_end_date);
CREATE INDEX idx_docs_withdrawn ON documents(withdrawn);
CREATE INDEX idx_docs_perpetual ON documents(perpetual_docket);
Powered by Datasette · Queries took 1.786ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API · Privacy